Trial Profile

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Liver cancer
Focus Therapeutic Use

Most Recent Events

04 Aug 2026 Actual primary completion date changed from 4 Sep 2025 to 1 Feb 2026.
03 Oct 2025 Status changed from active, no longer recruiting to discontinued because sponsor withdrew support from the study.
11 Sep 2025 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com